Prostate Cancer Trial, Recruiting NCT07197723 Sponsor: Memorial Sloan Kettering Cancer Center Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT07197723
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who do not currently have prostate cancer (for those not being treated at the trial site, this may be based on self-report)
  • People aged between 45 and 70 years old
  • People who were assigned male sex at birth (for those not being treated at the trial site, this may be based on self-report)
  • People who have had genetic testing completed at a clinically approved laboratory showing a BRCA1 or BRCA2 gene change that is confirmed as harmful or likely harmful, or whose doctor has documented this finding
  • People who are fluent in English, as the study surveys were designed and validated in English only

Who may not be able to join:

  • People with a serious psychiatric illness or significant cognitive impairment that study investigators believe would prevent them from participating
  • People who are unable to follow the study procedures, as determined by the study investigators or staff
  • People who are currently receiving active treatment for any cancer (people with a past history of cancer other than prostate cancer may still be considered eligible, as long as active treatment is not ongoing — confirm with trial site)
  • People who are already enrolled in a specific NCI study known as 19-C-0040 (Natural History of Men at High-Risk for Prostate Cancer), based on self-report
  • People who have a confirmed harmful or likely harmful gene change in any other hereditary prostate cancer risk gene besides BRCA1 or BRCA2, including genes such as HOXB13, ATM, CHEK2, NBN, PALB2, MLH1, MSH2, MSH6, PMS2, RAD51C, RAD51D, or TP53
  • People who have had a prostate biopsy within the past 36 months, based on clinical records or self-report for those not treated at the trial site

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jada Hamilton, PhD, MPH, Memorial Sloan Kettering Cancer Center

Phone: 646-888-0049

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
25 September 2025
Est. completion
1 September 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Intention to undergo prostate cancer screening options

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov